The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care

Trial Profile

The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Acronyms Toca7
  • Sponsors Tocagen
  • Most Recent Events

    • 09 Aug 2017 According to a Tocagen media release, the company is planning to start this trial in the first half of 2018.
    • 30 Sep 2016 According to a Tocagen media release, the company will present the data from this study at the 10th International Oncolytic Virus Meeting.
    • 10 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top